

Special Issue

Tumor-Targeting Radioligands for Molecular Imaging and Therapy

Message from the Guest Editors

Cancer is one of the leading causes of death worldwide. Timely diagnosis of the disease is of utmost importance to support informed decision making and to improve therapy efficacy. Radiopharmaceuticals are vital components of nuclear medicine encompassing such diagnostic methods as single-photon emission computed tomography (SPECT) or positron emission tomography (PET). The increasing development and successful clinical translation of novel radiopharmaceuticals for cancer therapy, such as [^{177}Lu]Lu-DOTATATE and [^{177}Lu]Lu-PSMA-617 paved the way for new and exciting research in the field of nuclear medicine. This Special Issue titled “Tumor-Targeting Radioligands for Molecular Imaging and Therapy” aims to provide the most recent developments and quests for novel ideal radiopharmaceutical for successful diagnosis, therapy or even theranostics of various tumors. You are kindly invited to contribute either with original article or a review.

Guest Editors

Dr. Petra Kolenc

Dr. Rosalba Mansi

Dr. Marko Krošelj

Deadline for manuscript submissions

closed (30 June 2023)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/107268

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)